Alpha Tau Medical Ltd. (DRTS) Form 6-K — Oct 19, 2026
Alpha Tau Medical announced FDA approval of an IDE supplement expanding its U.S. REGAIN trial of Alpha DaRT in recurrent glioblastoma from 10 to 20 patients. The updated protocol adds IDH-mutant grade 4 tumors, progression-free survival as a secondary endpoint, quality-of-life assessments, and an interim analysis six months after the fifth patient's July 2026 treatment. A REGAIN abstract from principal investigator Dr.
Key figures
- Trial sites
- 3
- Trial expansion
- REGAIN enrollment expanded from 10 to 20 patients
- Sno presentation date
- November 13, 2026
- Interim analysis timing
- six months after fifth patient's treatment (treated July 2026)
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.